Biotech Values

[DewDiligence]

DNA (93.50) is now trading about 5% above Roche’s cash offer. As noted, I think serious negotiations between Roche and DNA’s independent directors start at $100/sh.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”